You are here

vibegron

Urovant's lead drug disappoints in mid-stage study as first big FDA decision looms

Endpoints

Wed, 11/25/20 - 10:29 am

clinical trials

As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma

Fierce Biotech

Fri, 11/13/20 - 12:50 pm

overactive bladder

FDA sets Dec. PDUFA date for Urovant rival to Astellas drug

Fierce Biotech

Fri, 03/6/20 - 10:42 am

Urovant Sciences

overactive bladder

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival

Endpoints

Tue, 03/19/19 - 10:30 am

Alzheimer's disease

Vivek Ramaswamy

urinary incontinence

Urovant's overactive bladder drug scores in mid-stage trial

Endpoints

Thu, 11/1/18 - 11:32 am

Urovant Sciences

overactive bladder

clinical trials